GOOCH & HOUSEGO PLC (GHH) — Research Note

Executive summary

G&H is a UK-based specialist designer/manufacturer of advanced photonic components and systems (precision optics, acousto-optics, electro-optics, fibre optics) serving Aerospace & Defence, Industrial (incl. semiconductor equipment) and Life Sciences 2026-07-16 offer document. Trajectory has been a multi-year margin-repair story — FY25 revenue £150.5m / adj PBT £11.9m, with H1'26 revenue +15.5% to £81.9m and A&D revenue +51.7% driving order book to a record £167.3m 2026-06-02 interims. The single most important valuation point today is that on 16 July 2026 the board unanimously recommended a cash offer from Arlington Capital Partners at 1,230p + 4.9p interim div = 1,234.9p total, valuing equity at ~£345.6m and EV at ~£400.5m (25.9x adj EBIT TTM) 2026-07-16.

Fair value estimate

• Range: 1,200–1,235p per share → implied market cap £328m–£338m.
• Methodology: takeover-anchored fair value. With a unanimously recommended cash offer at 1,230p + retained 4.9p interim dividend = 1,234.9p total, and shareholder-vote-driven completion expected Q4 2026 subject to NSI Act and HSR clearance, fair value collapses to the offer level less a small break-risk discount. A standalone DCF/multiple approach (~20x FY26e adj PBT of ~£13m on £150–160m revenue and ~£30m net debt) would land at ~850–950p — well below the offer. Sector precedent multiples (photonics/optics M&A) are consistent with the 25.9x EV/EBIT bid.
• Current mcap £331.2m vs. mid-fair-value mcap ~£333m: ≈+2% upside to the deal, or roughly +2% total return over ~3–4 months if completion occurs on timetable. Downside if the deal breaks (Board's independent standalone value implied ~874p pre-bid) is on the order of −28%.
• View: fair — the market has efficiently priced in the offer.

Sector context

• Correctly classified Technology; more specifically a specialist photonics/industrial-technology franchise straddling Aerospace & Defence and semiconductor capital equipment.
• Quality profile is in line to slightly below typical sector peers on margins (adj op margin 8–10% in H1'26, target mid-teens medium term) 2026-06-02 but growth momentum, order-book coverage, and A&D exposure are above sector average given the current defence super-cycle.
• Listed peers: II-VI/Coherent (COHR), IPG Photonics (IPGP), HORIBA (6856), Halma (HLMA), Judges Scientific (JDG) — of these Judges and Halma are the closest UK-listed high-quality analogues.

Investment thesis (three bullets)

1. Cash takeover at a full price provides a hard floor and near-term ~2% arb return. The 1,230p + 4.9p combination is a 40.7% premium to the undisturbed price and 25.9x historic EV/adj EBIT — a full multiple that the Board describes as reflecting DCF fair value at an appropriate WACC 2026-07-16. Directors holding 0.44% have given irrevocables that survive higher competing offers.
2. Underlying franchise is genuinely improving. Order book up 16.5% cc to £167.3m (near-full FY26 cover), A&D revenue +51.7% in H1'26 with segment margin expanding to 10.2%, and the semiconductor/industrial market showing early recovery signs — production ramp at Global Photonics and Phoenix Optical adds capacity as demand accelerates 2026-06-02 interims, 2026-02-27 AGM update.
3. PE sponsor rationale de-risks completion. ACP is a specialist aerospace/defence investor with 27-year track record and $14bn AUM; regulatory approvals (NSI Act, HSR) are the primary conditions and G&H's defence-heavy customer base makes this a well-precedented deal type. J.P. Morgan is confirming cash resources; no financing conditionality 2026-07-16.

Key risks (three bullets)

1. Deal-break risk. If NSI or HSR clearance stalls or the scheme is not sanctioned by the 16 January 2027 long-stop, shares would likely reprice back to the undisturbed 874p (−28%) or lower 2026-07-16.
2. Germanium/raw-material inflation and supply concentration. Chinese export restrictions have driven germanium prices materially higher; G&H's scale limits its ability to fully absorb these in reporting periods, and any escalation could compress FY26 margins if the bid failed 2026-07-16 offer background; 2026-06-02 interims.
3. Second-half weighting risk in FY26. The Board has already flagged Q4-heavy revenue phasing owing to supply-chain constraints on order-book conversion — execution slip would matter more in a break scenario 2026-06-02 interims. Life Sciences margin has fallen to 4.6% on Pockels Cells wind-down (inferred: near-term drag).

Operating leverage

G&H is a moderate-operating-leverage industrial photonics business, not a high-fixed-cost software model. Gross margins run ~29–30% and adj operating margins have expanded from ~6% in H1'24 to 8.8% in H1'26 as volume grew 15.5% 2026-06-02. Revenue growth of ~15% delivered adj op profit growth of ~17% — decent but not dramatic incremental drop-through, consistent with an asset-heavy multi-site manufacturing footprint (11 sites plus contract manufacturers). Segment-level leverage is visible in A&D, where revenue +51.7% converted a £(1.6)m loss into £3.6m operating profit — a ~£5m swing on ~£12m of incremental revenue, implying ~40% incremental margin from operational fixed-cost absorption at Moorpark and Ilminster 2026-06-02. Management targets mid-teens medium-term margins; a 10–20% revenue beat would plausibly add ~50–70% to operating profit given current sub-scale utilisation. However, materials cost inflation (germanium, tariffs) tempers the drop-through. Score: mid-to-upper range for a specialty industrial — not a network-effect or platform business.

Value-trap signals

None identified in the classic sense — the shares are trading at a fair takeover multiple, not distressed. However: (i) the Board's own comment that G&H is "smaller-scale" versus consolidating competitors and struggles with UK small-cap liquidity and remuneration constraints is effectively a soft admission that public-company standalone value creation is capped 2026-07-16; (ii) the FY26 Life Sciences margin collapse (12.0%→4.6%) and Pockels Cells wind-down show a structurally challenged product line; (iii) germanium supply concentration on China is a persistent inflation drag.

Earnings vs. expectations

Track record is mixed but improving. FY24 saw a downgrade (15 Aug 2024 trading update flagged adj PBT ~£1.5m below expectations due to supply/customer delays) 2024-08-15. FY25 was in line to slightly ahead (7 Oct 2025 update noted trading "broadly in line" with a stronger H2). FY26 H1 delivered in line with prior guidance; the 27 Feb 2026 AGM update reiterated confidence, and 9 April 2026 stated "in line with management's expectations". Prior periods included a c.£3m FY24 downgrade at Feb 2024 AGM due to industrial/medical laser destocking. Net pattern: a couple of visible misses in FY22–FY24 during pandemic/destocking, followed by steady in-line-to-slightly-ahead delivery through FY25–H1'26. Not a clean beat-record.

Conviction

Conviction: 5 (very high). The recommended cash offer at 1,230p + 4.9p is a hard, disclosed, unanimously recommended anchor. The FV call is essentially arithmetic: pay 1,210p, receive 1,234.9p on completion, subject only to regulatory approval risk. Anchoring factors: (i) irrevocables from all director-shareholders binding through higher offers; (ii) equity-financed (no debt condition); (iii) two independent financial advisers (Investec, Rothschild) have opined the price fair. Limiting factor: regulatory/deal-break tail risk on NSI and HSR.

Overall assessment for the investor profile

Even though the FV work is high-conviction, this stock is a poor fit for the strategy. Upside is capped at ~2%, the equity story ends with delisting, and the AI-receiver angle (semiconductor equipment optics, A&D directed-energy, space laser comms) is real but modest and no longer available to public investors post-Q4 2026. There is no long-tail upside from operating leverage or an AI re-rating — the sponsor captures it. The buyer would be exchanging a fair AI-tangential compounder for a merger-arb bond return.